公开(公告)号：US20220031631A1

公开(公告)日：2022-02-03

申请号：US17277423

申请日：2019-09-19

Applicant: ModernaTX, Inc.

Inventor： Örn Almarsson ,  Jin Lim ,  Eugene Cheung ,  Jaclyn Milton

IPC: A61K9/51 ,  A61K8/86 ,  C08G65/332

Abstract: The present disclosure is based, at least in part, on the discovery that high-purity PEG lipids exhibit superior physical and biological properties, particularly when used in lipid nanoparticle (LNP) formulations. Therefore, the present disclosure provides PEG lipids at a recommended purity, e.g., for use in formulations, such as LNP formulations. The present disclosure also provides LNPs comprising the high-purity PEG lipids, and methods for delivering therapeutic agents to a subject using the same.

公开(公告)号：US11203569B2

公开(公告)日：2021-12-21

申请号：US16493789

申请日：2018-03-15

Applicant: ModernaTX, Inc.

Inventor： Orn Almarsson ,  Eugene Cheung

IPC: C07C229/24 ,  C07C55/07 ,  C07C65/03 ,  C07C227/16 ,  C07C229/12

Abstract: Provided herein are novel solid forms of each of four compounds: (1) heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate (“Compound 1”), (2) heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate (“Compound 2”), (3) heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (“Compound 3”), and (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (“MC3”), and related compositions and methods.